Gain Therapeutics (GANX) announced the pricing of a public offering of 4.50M shares at $1.55 per share. Newbridge Securities is acting as the sole book-running manager for the offering. The offering is expected to close on or about July 17. Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson’s disease and for general corporate purposes. The stock in premarket trading is down 6% to $1.59.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Gain Therapeutics announces common stock, warrants offering
- Buy Rating for Gain Therapeutics Driven by Accelerated Clinical Progress and Valuation Model
- Promising Developments and Strategic Advancements Propel Gain Therapeutics to ‘Buy’ Rating
- Positive Outlook for Gain Therapeutics Amid Promising Biomarker Developments and Clinical Trial Progress
- Gain Therapeutics Advances Phase 1b Parkinson’s Study